Frequency of Painful Physical Symptoms With Major Depressive Disorder in Asia: Relationship With Disease Severity and Quality of Life

Phil Lee, Mingyuan Zhang, Jin Pyo Hong, Hong-Choon Chua, Kuang-Peng Chen, Siu Wa Tang, Benjamin T. M. Chan, Min Soo Lee, Bobbie Lee, Gabrielle L. Gallagher, and Martin Dossenbach

Published: December 2, 2008

Article Abstract

Objective: Patients with major depressive disorder (MDD) frequently report concomitant painful physical symptoms, which may negatively impact diagnosis and treatment. The purpose of this study was to estimate the frequency of painful physical symptoms in Asian patients treated for an acute episode of MDD and to describe the associated demographics, clinical status, treatment patterns, and socioeconomic burden.

Method: This multicountry, observational study enrolled 909 patients with MDD (DSM-IV-TR or ICD-10 criteria) in the psychiatric care setting from June 14, 2006, to February 15, 2007. Patients were classified as positive for painful physical symptoms (PPS+) if they achieved a mean score ≥ 2 on the modified Somatic Symptom Inventory. The Clinical Global Impressions-Severity of Illness scale (CGI-S) and 17-item Hamilton Rating Scale for Depression (HAM-D 17) determined depression severity, and the EuroQoL Questionnaire-5 dimensions (EQ-5D) assessed subjective well-being.

Results: Overall, 51.8% of patients were classified as PPS+. PPS+ patients were more likely to be female (72.2% vs. 65.1%, p =.022), had relatively more medical comorbidity (29.7% vs. 21.0% with ≥ 1 comorbidity, p =.003), were more significantly depressed (CGI-S mean [SE] score = 4.84 [0.03] vs. 4.63 [0.04], p17 mean [SE] score = 24.80 [0.26] vs. 22.39 [0.27], p

Conclusion: Painful physical symptoms are experienced by approximately half of patients with MDD in Asia and are associated with poor clinical status and perceived quality of life.

Volume: 69

Quick Links: Pain , Somatic Symptoms and Related Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...